But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.